ClinicalTrials.gg
CompletedNCT01243671Updated Jul 25, 2014Results posted

A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease

A Phase 3 interventional study of Adalimumab in Intestinal Behçet's Disease, sponsored by AbbVie (prior sponsor, Abbott). Completed at 12 sites in Japan. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2014-07-25.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
15 Years and older
Sex
All
01

Study summary

To investigate efficacy, safety and pharmacokinetics of adalimumab subcutaneous (sc) for Japanese subjects with intestinal Behçet's disease who are refractory to conventional therapies.

02

Conditions studied

  • Intestinal Behçet's Disease

Keywords

  • Behçet's, intestinal
03

In context

Lead sponsor

AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Intestinal Behçet's disease
  • Patients with typical ulcer at ileocecal region
  • Patients who have failed conventional treatment

Exclusion criteria

Exclusion Criteria:

  • Crohn's disease
  • History of ileocecal resection
  • History of tuberculosis (TB)
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant during the study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Adalimumab

    Adalimumab 160 mg at Week 0, 80 mg at Week 2 and 40 mg every other week (eow) starting at Week 4 to Week 50, subcutaneous injection. After Week 52, participants could continue the treatment with 40 mg eow until the day before approval of adalimumab for intestinal Behçet's disease in Japan.

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Number of Participants With Marked Improvement at Week 24

    Marked improvement is defined as the combination of both global assessment of gastrointestinal (GI) symptoms and endoscopic improvement grades of ≤1. Global assessment of GI symptoms is a participant-assessed, investigator-confirmed grading of global symptoms from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Endoscopic improvement was assessed in 4 grades compared to the screening endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion).

    Time frame: 24 weeks

Secondary outcomes

  1. Number of Participants With Marked Improvement at Week 52

    Marked improvement is defined as the combination of both global assessment of gastrointestinal (GI) symptoms and endoscopic improvement grades of ≤1. Global assessment of GI symptoms is a participant-assessed, investigator-confirmed grading of global symptoms from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Endoscopic improvement was assessed in 4 grades compared to the screening endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion).

    Time frame: 52 weeks

  2. Number of Participants With Complete Remission at Week 24 and Week 52

    Complete remission was defined as both endoscopic improvement and global assessment of gastrointestinal symptoms grades of 0. Endoscopic improvement was assessed in 4 grades compared to the screening (baseline) endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion). Global assessment of gastrointestinal symptoms is a participant-assessed, investigator-confirmed grading of global symptoms from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life.

    Time frame: 24 weeks, 52 weeks

  3. Number of Participants With a Global Assessment of Gastrointestinal Symptoms Grade 0 or ≤1 and Improvement of ≥1 Grade at Week 24 and Week 52

    Study participants completed a global assessment of their gastrointestinal symptoms (Behçet's disease symptoms other than gastrointestinal symptoms were excluded) during 2 weeks before assessment visit on a 5-grade scale. The investigator confirmed this assessment via interview with participants. Assessment is graded from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Global assessment of grade 0 or ≤1 and improvement of ≥1 (from baseline) is presented.

    Time frame: 24 weeks, 52 weeks

  4. Number of Participants With Endoscopic Improvement Grades 0, ≤1 and ≤2 at Week 24 and Week 52

    Endoscopic improvement was assessed in 4 grades compared to the screening (baseline) endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion).

    Time frame: 24 weeks, 52 weeks

  5. Number of Participants With Abdominal Pain, Diarrhea and Other Gastrointestinal (GI) Symptoms Grade ≤1 and Improvement of ≥1 Grade at Week 24 and Week 52

    Participants assessed their abdominal pain, diarrhea and other gastrointestinal symptoms (abdominal discomfort, abdominal fullness, etc) during 2 weeks before assessment visit in 5 grades. Investigator confirmed the assessment through interview with participants. Assessment is graded from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Improvement of ≥1 grade from baseline is also presented.

    Time frame: 24 weeks, 52 weeks

  6. Number of Participants With Resolution of Behçet's Disease Symptoms (Other Than Gastrointestinal Symptoms) at Week 24 and Week 52

    Investigators assessed oral aphthous (mouth ulcers), skin symptoms, eye symptoms and vulval (genital) ulcers during 4 weeks before study visit via participant interview, using the following grades. Oral aphthous: 0=None; 1=Symptom existed less than 2 weeks in recent 4 weeks; 2=Symptom existed 2 weeks or more in recent 4 weeks; 3=Symptom existed mostly in recent 4 weeks. Skin (Erythema nodosum rash): 0=None; 1=Symptom existed less than 2 weeks in recent 4 weeks; 2=Symptom existed 2 weeks or more in recent 4 weeks; 3=Symptom existed mostly in recent 4 weeks. Eye (Uveitis): 0=None; 1=one eye crisis in recent 4 weeks; 2=two eye crises in recent 4 weeks; 3=three eye crises in recent 4 weeks. Vulval (genital) ulcer: 0=None; 1=Symptom existed less than 2 weeks in recent 4 weeks; 2=Symptom existed 2 weeks or more in recent 4 weeks; 3=Symptom existed mostly in recent 4 weeks. Resolution was defined as: Behçet's disease symptoms other than gastrointestinal symptoms were graded 0 (disappeared).

    Time frame: 24 weeks, 52 weeks

  7. Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 24 and Week 52

    Inflammatory Bowel Disease Questionnaire (IBDQ) is the standard questionnaire to assess the quality of life of patients with inflammatory bowel disease. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function and emotional status. The responses to each question within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

    Time frame: Baseline, 24 weeks, 52 weeks

  8. Mean Change From Baseline in Short Form-36 (SF-36) Summary Scores at Week 24 and Week 52

    The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain and rating of one's health. Score on the physical component ranges from 0 (poorest health) to 100 (best health). The mental component reflects vitality, social functioning, role-emotional and mental health. Score on the mental component ranges from 0 (poorest health) to 100 (best health).

    Time frame: Baseline, 24 weeks, 52 weeks

  9. Median Change From Baseline in C-Reactive Protein (CRP) at Week 24 and Week 52

    C-Reactive Protein (CRP) normal range was defined as ≤0.3 mg/dL.

    Time frame: Baseline, 24 weeks, 52 weeks

07

Results

Posted May 15, 2013

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab
Started20
Completed 24 weeks of treatment18
Completed 52 weeks of treatment17
Completed15
Not completed5
Withdrew: Adverse event3
Withdrew: Anti-adalimumab antibody positive1
Withdrew: Other1

Outcome measures

PrimaryNumber of Participants With Marked Improvement at Week 24

Marked improvement is defined as the combination of both global assessment of gastrointestinal (GI) symptoms and endoscopic improvement grades of ≤1. Global assessment of GI symptoms is a participant-assessed, investigator-confirmed grading of global symptoms from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Endoscopic improvement was assessed in 4 grades compared to the screening endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion).

Time frame:
24 weeks
Reported as:
Number · participants
Number of Participants With Marked Improvement at Week 24
participantsAdalimumab
Number of Participants With Marked Improvement at Week 249
SecondaryNumber of Participants With Marked Improvement at Week 52

Marked improvement is defined as the combination of both global assessment of gastrointestinal (GI) symptoms and endoscopic improvement grades of ≤1. Global assessment of GI symptoms is a participant-assessed, investigator-confirmed grading of global symptoms from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Endoscopic improvement was assessed in 4 grades compared to the screening endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion).

Time frame:
52 weeks
Reported as:
Number · participants
Number of Participants With Marked Improvement at Week 52
participantsAdalimumab
Number of Participants With Marked Improvement at Week 5212
SecondaryNumber of Participants With Complete Remission at Week 24 and Week 52

Complete remission was defined as both endoscopic improvement and global assessment of gastrointestinal symptoms grades of 0. Endoscopic improvement was assessed in 4 grades compared to the screening (baseline) endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion). Global assessment of gastrointestinal symptoms is a participant-assessed, investigator-confirmed grading of global symptoms from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life.

Time frame:
24 weeks, 52 weeks
Reported as:
Number · participants
Number of Participants With Complete Remission at Week 24 and Week 52
participantsAdalimumab
Week 244
Week 524
SecondaryNumber of Participants With a Global Assessment of Gastrointestinal Symptoms Grade 0 or ≤1 and Improvement of ≥1 Grade at Week 24 and Week 52

Study participants completed a global assessment of their gastrointestinal symptoms (Behçet's disease symptoms other than gastrointestinal symptoms were excluded) during 2 weeks before assessment visit on a 5-grade scale. The investigator confirmed this assessment via interview with participants. Assessment is graded from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Global assessment of grade 0 or ≤1 and improvement of ≥1 (from baseline) is presented.

Time frame:
24 weeks, 52 weeks
Reported as:
Number · participants
Number of Participants With a Global Assessment of Gastrointestinal Symptoms Grade 0 or ≤1 and Improvement of ≥1 Grade at Week 24 and Week 52
participantsAdalimumab
Week 24: Grade 09
Week 24: Grade ≤113
Week 24: Improvement of ≥1 Grade16
Week 52: Grade 09
Week 52: Grade ≤116
Week 52: Improvement of ≥1 Grade18
SecondaryNumber of Participants With Endoscopic Improvement Grades 0, ≤1 and ≤2 at Week 24 and Week 52

Endoscopic improvement was assessed in 4 grades compared to the screening (baseline) endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion).

Time frame:
24 weeks, 52 weeks
Reported as:
Number · participants
Number of Participants With Endoscopic Improvement Grades 0, ≤1 and ≤2 at Week 24 and Week 52
participantsAdalimumab
Week 24: Grade 09
Week 24: Grade ≤112
Week 24: Grade ≤215
Week 52: Grade 011
Week 52: Grade ≤113
Week 52: Grade ≤215
SecondaryNumber of Participants With Abdominal Pain, Diarrhea and Other Gastrointestinal (GI) Symptoms Grade ≤1 and Improvement of ≥1 Grade at Week 24 and Week 52

Participants assessed their abdominal pain, diarrhea and other gastrointestinal symptoms (abdominal discomfort, abdominal fullness, etc) during 2 weeks before assessment visit in 5 grades. Investigator confirmed the assessment through interview with participants. Assessment is graded from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Improvement of ≥1 grade from baseline is also presented.

Time frame:
24 weeks, 52 weeks
Reported as:
Number · participants
Number of Participants With Abdominal Pain, Diarrhea and Other Gastrointestinal (GI) Symptoms Grade ≤1 and Improvement of ≥1 Grade at Week 24 and Week 52
participantsAdalimumab
Week 24: Abdominal Pain Grade ≤1; n=1811
Week 24: Diarrhea Grade ≤1; n=1613
Week 24: Other GI Symptom Grade ≤1; n=2016
Week 24:Abdominal Pain Improvement ≥1 Grade; n=1814
Week 24: Diarrhea Improvement ≥1 Grade; n=1611
Week 24:Other GI Symptom Improvement ≥1 Grade;n=2018
Week 52: Abdominal Pain Grade ≤1; n=1814
Week 52: Diarrhea Grade ≤1; n=1615
Week 52: Other GI Symptom Grade ≤1; n=2016
Week 52:Abdominal Pain Improvement ≥1 Grade; n=1816
Week 52: Diarrhea Improvement ≥1 Grade; n=1613
Week 52:Other GI Symptom Improvement ≥1 Grade;n=2018
SecondaryNumber of Participants With Resolution of Behçet's Disease Symptoms (Other Than Gastrointestinal Symptoms) at Week 24 and Week 52

Investigators assessed oral aphthous (mouth ulcers), skin symptoms, eye symptoms and vulval (genital) ulcers during 4 weeks before study visit via participant interview, using the following grades. Oral aphthous: 0=None; 1=Symptom existed less than 2 weeks in recent 4 weeks; 2=Symptom existed 2 weeks or more in recent 4 weeks; 3=Symptom existed mostly in recent 4 weeks. Skin (Erythema nodosum rash): 0=None; 1=Symptom existed less than 2 weeks in recent 4 weeks; 2=Symptom existed 2 weeks or more in recent 4 weeks; 3=Symptom existed mostly in recent 4 weeks. Eye (Uveitis): 0=None; 1=one eye crisis in recent 4 weeks; 2=two eye crises in recent 4 weeks; 3=three eye crises in recent 4 weeks. Vulval (genital) ulcer: 0=None; 1=Symptom existed less than 2 weeks in recent 4 weeks; 2=Symptom existed 2 weeks or more in recent 4 weeks; 3=Symptom existed mostly in recent 4 weeks. Resolution was defined as: Behçet's disease symptoms other than gastrointestinal symptoms were graded 0 (disappeared).

Time frame:
24 weeks, 52 weeks
Reported as:
Number · participants
Number of Participants With Resolution of Behçet's Disease Symptoms (Other Than Gastrointestinal Symptoms) at Week 24 and Week 52
participantsAdalimumab
Week 24: Oral Aphthous; n=1510
Week 24: Skin (Erythema nodosum rash); n=86
Week 24: Eye (Uveitis); n=00
Week 24: Vulval (Genital) Ulcer; n=32
Week 52: Oral Aphthous; n=1510
Week 52: Skin (Erythema nodosum rash); n=87
Week 52: Eye (Uveitis); n=00
Week 52: Vulval (Genital) Ulcer; n=32
SecondaryMean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 24 and Week 52

Inflammatory Bowel Disease Questionnaire (IBDQ) is the standard questionnaire to assess the quality of life of patients with inflammatory bowel disease. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function and emotional status. The responses to each question within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

Time frame:
Baseline, 24 weeks, 52 weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 24 and Week 52
units on a scaleAdalimumab
Week 2437.1 ± 40.00
Week 5241.2 ± 41.91
SecondaryMean Change From Baseline in Short Form-36 (SF-36) Summary Scores at Week 24 and Week 52

The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain and rating of one's health. Score on the physical component ranges from 0 (poorest health) to 100 (best health). The mental component reflects vitality, social functioning, role-emotional and mental health. Score on the mental component ranges from 0 (poorest health) to 100 (best health).

Time frame:
Baseline, 24 weeks, 52 weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline in Short Form-36 (SF-36) Summary Scores at Week 24 and Week 52
units on a scaleAdalimumab
Week 24: Summary Score (Physical Component)7.5 ± 7.18
Week 24: Summary Score (Mental Component)8.9 ± 12.85
Week 52: Summary Score (Physical Component)9.0 ± 8.42
Week 52: Summary Score (Mental Component)9.0 ± 13.27
SecondaryMedian Change From Baseline in C-Reactive Protein (CRP) at Week 24 and Week 52

C-Reactive Protein (CRP) normal range was defined as ≤0.3 mg/dL.

Time frame:
Baseline, 24 weeks, 52 weeks
Reported as:
Mean · mg/dL
Median Change From Baseline in C-Reactive Protein (CRP) at Week 24 and Week 52
mg/dLAdalimumab
Week 24-0.3 ± 1.27
Week 52-0.2 ± 2.22

Adverse events

Collected over Adverse Events (AEs) were reported from the time of study drug administration up to 124 weeks + 70 days following discontinuation of study drug. Serious AEs were collected from the time the participant signed the study-specific informed consent.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab—6/20 (30%)20/20 (100%)
Most frequent serious events
Most frequent serious events
EventAdalimumab
AUTOIMMUNE THYROIDITISEndocrine disorders1/20
INTESTINAL OBSTRUCTIONGastrointestinal disorders1/20
LOWER GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders1/20
SUBILEUSGastrointestinal disorders1/20
BEHCET'S SYNDROMEImmune system disorders1/20
ABSCESS INTESTINALInfections and infestations1/20
APPENDICITISInfections and infestations1/20
APPENDICITIS PERFORATEDInfections and infestations1/20
SPONDYLITIC MYELOPATHYNervous system disorders1/20
Most frequent other events
Showing 10 of 103
Most frequent other events
EventAdalimumab
NASOPHARYNGITISInfections and infestations11/20
HEADACHENervous system disorders5/20
BACK PAINMusculoskeletal and connective tissue disorders4/20
COUGHRespiratory, thoracic and mediastinal disorders4/20
DENTAL CARIESGastrointestinal disorders3/20
DIARRHOEAGastrointestinal disorders3/20
BEHCET'S SYNDROMEImmune system disorders3/20
GASTROENTERITISInfections and infestations3/20
CONTUSIONInjury, poisoning and procedural complications3/20
RASHSkin and subcutaneous tissue disorders3/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)Adalimumab
Mean42.4 ± 13.33
Age, Customized
Age, Customized(participants)Adalimumab
<40 years11
Between 40 and 65 years7
>=65 years2
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab
Female10
Male10
Longest Diameter of Ileocecal Largest Open Ulcer
Longest Diameter of Ileocecal Largest Open Ulcer(participants)Adalimumab
>=1 cm to <2 cm8
>=2 cm to <3 cm5
>=3 cm7
Global Assessment of Gastrointestinal (GI) Symptoms Grade
Global Assessment of Gastrointestinal (GI) Symptoms Grade(participants)Adalimumab
Grade 00
Grade 10
Grade 20
Grade 315
Grade 45
Assessment of Abdominal Pain (GI Symptom Component) Grade
Assessment of Abdominal Pain (GI Symptom Component) Grade(participants)Adalimumab
Grade 02
Grade 11
Grade 23
Grade 310
Grade 44
Assessment of Diarrhea (GI Symptom Component) Grade
Assessment of Diarrhea (GI Symptom Component) Grade(participants)Adalimumab
Grade 04
Grade 16
Grade 20
Grade 39
Grade 41
Assessment of Other Symptoms (GI Symptom Component) Grade
Assessment of Other Symptoms (GI Symptom Component) Grade(participants)Adalimumab
Grade 00
Grade 11
Grade 24
Grade 312
Grade 43

4 further baseline measures are reported on the registry.

08

Study locations

12 sites
  • Site Reference ID/Investigator# 46738
    Chikushino, Japan
  • Site Reference ID/Investigator# 46723
    Kurume, Japan
  • Site Reference ID/Investigator# 46728
    Nagoya-shi, Japan
  • Site Reference ID/Investigator# 46725
    Nishinomiya-shi, Japan
  • Site Reference ID/Investigator# 46730
    Osaka-shi, Japan
  • Site Reference ID/Investigator# 46722
    Sagamihara-shi, Japan
  • Site Reference ID/Investigator# 46726
    Sakura, Japan
  • Site Reference ID/Investigator# 59578
    Sapporo-shi, Japan
  • Site Reference ID/Investigator# 46724
    Takatsuki-shi, Japan
  • Site Reference ID/Investigator# 46729
    Tokyo, Japan
  • Site Reference ID/Investigator# 46737
    Tokyo, Japan
  • Site Reference ID/Investigator# 46733
    Yokohama-shi, Japan
09

References and documents

Publications

  • Inoue N, Kobayashi K, Naganuma M, Hirai F, Ozawa M, Arikan D, Huang B, Robinson AM, Thakkar RB, Hibi T. Long-term safety and efficacy of adalimumab for intestinal Behcet's disease in the open label study following a phase 3 clinical trial. Intest Res. 2017 Jul;15(3):395-401. doi: 10.5217/ir.2017.15.3.395. Epub 2017 Jun 12. PubMed 28670237 ↗
  • Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B, Watanabe K, Mitsuyama K, Inoue T, Ishigatsubo Y, Suzuki Y, Nagahori M, Motoya S, Nakamura S, Arora V, Robinson AM, Thakkar RB, Hibi T. Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol. 2015 May;13(5):940-8.e3. doi: 10.1016/j.cgh.2014.08.042. Epub 2014 Sep 19. PubMed 25245624 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Mar 2012 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2010
First posted
Nov 18, 2010
Start
Oct 2010
Primary completionActual
Mar 2012
CompletionActual
Jun 2013
Results first posted
May 15, 2013
Last update
Jul 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01243671
Collaborators
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Nov 18, 2010
Start date
Oct 2010
Primary completion
Mar 2012
Completion
Jun 2013
Results posted
May 15, 2013
Last update
Jul 25, 2014

Study contacts

Morio Ozawa, MS
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion